Placebo + Cisapride
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Infant, Premature
Conditions
Infant, Premature, Infant, Newborn
Trial Timeline
Mar 1, 2003 → Jul 1, 2003
NCT ID
NCT01281566About Placebo + Cisapride
Placebo + Cisapride is a approved stage product being developed by Johnson & Johnson for Infant, Premature. The current trial status is terminated. This product is registered under clinical trial identifier NCT01281566. Target conditions include Infant, Premature, Infant, Newborn.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01281553 | Approved | Terminated |
| NCT01281566 | Approved | Terminated |
Competing Products
20 competing products in Infant, Premature
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TSHA-101 | Taysha Gene Therapies | Phase 1/2 | 36 |
| somatropin | Eli Lilly | Phase 3 | 77 |
| RotaTeq (V260) + IPV | Merck | Phase 3 | 77 |
| recombinant somatropin | Merck | Pre-clinical | 23 |
| Recombinant human growth hormone (r-hGH) | Merck | Phase 3 | 77 |
| MAS825 + Placebo | Novartis | Phase 2 | 52 |
| epoetin beta + epoetin beta | Roche | Pre-clinical | 23 |
| Genotropin (PN-180,307) Somatropin + Control-no treatment | Pfizer | Phase 3 | 76 |
| Prevenar (13v) | Pfizer | Pre-clinical | 22 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| rhBSSL + Placebo | Swedish Orphan Biovitrum | Phase 2 | 51 |
| DT5aP-IPV-Hib 5-component Pertussis vaccine + DT3aP-HBs-IPV | Sanofi | Phase 3 | 76 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 2 | 51 |
| Bacillus Clausii Multi ATB Resist + Placebo | Sanofi | Approved | 84 |
| Radiprodil | UCB | Phase 2 | 49 |
| Larotrectinib (Vitrakvi, BAY2757556) + Standard of Care | Bayer | Pre-clinical | 20 |
| Sabril® | Lundbeck | Pre-clinical | 20 |
| Vigabatrin | Lundbeck | Approved | 82 |
| Nusinersen | Biogen | Pre-clinical | 20 |